Month: August 2020

West Palm Beach, Florida, Aug. 20, 2020 (GLOBE NEWSWIRE) — Colonnade Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units will be listed on The New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “CLA.U” beginning on August 21, 2020. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a price of $11.50 per share. After the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “CLA” and “CLA WS,” respectively. The offering is expected to close on August 25, 2020.BTIG, LLC is acting as the sole book running...

WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the pricing of its upsized initial public offering of 8,684,800 common shares at a public offering price of $20.00 per share. All of the shares are being offered by Kymera. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Kymera, are expected to be approximately $173.7 million. Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,302,720 common shares at the initial public offering price.The shares...

In a Phase 1 study in the U.S., at 7 days after a second dose of 30ug, BNT162b2 elicited SARS-CoV-2–neutralizing geometric mean titers (GMTs) in younger adults (18-55 years of age) that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 times the GMT of the same panel, demonstrating strong immunogenicity in younger and older adults.The companies previously announced that BNT162b2-vaccinated human participants displayed a favorable breadth of epitopes recognized in T cell responses specific to the SARS-CoV-2 spike antigen, and that BNT162b2 demonstrated concurrent induction of high magnitude CD4+ and CD8+ T cell responses against the receptor binding domain (RBD) and against the remainder of the spike glycoproteinAcross...

BNT162b2 induzierte in einer Phase-1-Studie in den USA 7 Tage nach der zweiten 30µg-Dosis mit BNT162b2 in jüngeren Erwachsenen (18-55 Jahre) SARS-CoV-2-neutralisierende geometrische Titer-Mittelwerte (GMT), die dem 3,8-fachen GMT eines Panels aus Rekonvaleszenz-Seren von 38 Patienten entsprachen. In älteren Erwachsenen (65-85 Jahre) induzierte der Impfstoffkandidat einen neutralisierenden GMT, der dem 1,6-fachen GMT des gleichen Panels entsprach und zeigte zudem in jüngeren wie in älteren Erwachsenen eine starke ImmunogenitätWie bereits von den Unternehmen bekanntgegeben, zeigten mit BNT162b2 geimpfte Probanden eine vorteilhaftere Breite an Epitopen, die in T-Zell-Reaktionen erkannt werden, die spezifisch für das SARS-CoV-2-Spike-Antigen sind. Außerdem zeigte BNT162b2 eine gleichzeitige Induktion von hochgradigen CD4+- und CD8+-T-Zellreaktionen...

TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) — Itafos (TSX-V: IFOS) (the “Company”) provided today an update on Itafos Conda’s previously announced reduced scope plant turnaround and announced a disruption in sulfuric acid supply to Itafos Conda from Rio Tinto’s Kennecott mine.The Company previously announced its decision to conduct a reduced scope plant turnaround at Itafos Conda during July 2020 as part of its risk mitigation measures during the COVID-19 pandemic. The reduced scope plant turnaround focused on inspection, testing and preventative maintenance of critical equipment. Itafos Conda completed the reduced scope plant turnaround with no environmental releases or reportable injuries.The Company further announced today that Itafos Conda has been experiencing a significant disruption in sulfuric acid supply from Rio Tinto’s Kennecott...

TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) — Class 1 Nickel and Technologies Limited (“Class 1 Nickel” or the “Company”) (CSE: NICO), a Canadian company aiming to develop nickel-copper-cobalt sulphide deposits 45km northeast of Timmins, Ontario, today announces the issuance of 130,769 common shares in the capital of the Company (“Common Shares”) at a price of $0.65 per Common Share, being the closing price of the Common Shares on the date of issuance. The issuance of Common Shares maintains the Company’s option to earn a 100% undivided interest from Quebec Precious Metals Corporation (“QPM”) in the Somanike Property, an exploration stage property consisting of 5146.06 hectares located in La Motte, Quebec. A copy of the option agreement concerning the Somanike Property dated April 27, 2020 (the “Option Agreement”) was filed under Class...

TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital”) today announced its financial and operating results for the three-month and six-month periods ended June 30, 2020. Financial references are in Canadian dollars unless otherwise specified.2020 Second Quarter HighlightsEstimated book value at the end of Q2 of approximately $0.49 per share; year-to-date (YTD) growth of more than 8% from the book value at the year-end December 31, 2019Completed a share consolidation resulting in 32,934,077 common shares post-consolidationQ2 total revenue under IFRS $1,835,000; YTD $2,928,000YTD net loss from continuing operations of $342,000YTD adjusted EBITDA(1) of $836,000Generated YTD cash from operations of $663,000“In the second quarter, we continued to focus on improving our operating efficiency and resource...

バミューダ諸島ハミルトン発, Aug. 21, 2020 (GLOBE NEWSWIRE) — エンスター･グループ･リミテッド (Enstar Group Limited、以下「エンスター」) (NASDAQ: ESGR) は本日、子会社であるエンスター･ファイナンス (Enstar Finance LLC) が、2040年満期、5.750%固定金利リセット型下位劣後債 (以下「本債」) の価格を元本総額3億5,000万ドル (約371億3000万円) と設定し、本債はエンスターが劣後基準で完全かつ無条件に保証することを発表した。本募集は、慣例的な終了条件を満たすことを条件に、2020年8月26日に終了する予定となっている。エンスターは、公募による純手取り金と手元現金で、タームローンの借入残高約3億5,000万ドル (約371億3000万円) を返済する予定である。ウェルズ･ファーゴ証券 (Wells Fargo Securities)、バークレイズ (Barclays)、HSBC、JPモルガン (J.P. Morgan)、ING、nab証券 (nabSecurities, LLC)、スコシアバンク (Scotiabank)、Truist Securitiesが共同主幹事を務め、コメルツ銀行 (COMMERZBANK) とオーストラリア･コモンウェルス銀行 (Commonwealth Bank of Australia) が上級副幹事、BMOキャピタルマーケッツ (BMO Capital Markets) とロイズ証券 (Lloyds Securities) が下級副幹事を務めている。債券の募集は、米国証券取引委員会 (以下「SEC」) に提出済みの有効な登録届出書に基づいて行われる。本プレスリリースは、売り出しの申込みまたは買い付け申込みの勧誘を構成するものではなく、当該州または管轄区の証券法に基づく登録または資格取得前に、当該申込み、勧誘または販売活動が違法となるような州または管轄区における有価証券の販売を行うものではない。売り出しまたは買い付けの勧誘は、SECに提出された目論見書および関連する目論見書補完書面のみをもって行われる。これらの文書は、SEC...

TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) — Asian Mineral Resources Limited (the “Company”) (ASN-TSX Venture) is pleased to announce it has retained Hybrid Financial Ltd. (“Hybrid”) to provide investor relations services to the Company, pursuant to a consulting agreement dated August 20, 2020.  Hybrid has been engaged to heighten market and brand awareness for Asian Mineral Resources Limited and to broaden the Company’s reach within the investment community (the “Services”). In consideration for these Services the Company has agreed to pay Hybrid a fee of $15,000 per month plus applicable taxes for a six-month period.

MALVERN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Arnold Baskies, M.D. and Andrew Drechsler, have been appointed to the Company’s Board of Directors.Dr. Baskies is a past Chief Science Officer and Chairman of the National Board of Directors of the American Cancer Society. He is a fellowship trained surgical oncologist recognized with numerous major awards in the field. Mr. Drechsler serves as the Chief Financial Officer of Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, and previously as Chief Financial Officer of Insmed Incorporated.“We are pleased to welcome both Arnold Baskies, M.D. and Andy Drechsler to Baudax’s Board,” said Alfred...